TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Given Average Rating of “Moderate Buy” by Brokerages

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) has been assigned an average recommendation of “Moderate Buy” from the five analysts that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $10.50.

Several research firms have issued reports on TLSI. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of TriSalus Life Sciences in a research note on Monday. Wall Street Zen raised shares of TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research note on Friday, November 28th.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in TLSI. Charles Schwab Investment Management Inc. acquired a new position in TriSalus Life Sciences during the first quarter valued at approximately $55,000. Goldman Sachs Group Inc. acquired a new stake in shares of TriSalus Life Sciences in the first quarter worth $187,000. Connective Capital Management LLC raised its stake in shares of TriSalus Life Sciences by 12.8% in the 2nd quarter. Connective Capital Management LLC now owns 32,796 shares of the company’s stock valued at $179,000 after acquiring an additional 3,717 shares during the period. Police & Firemen s Retirement System of New Jersey purchased a new position in shares of TriSalus Life Sciences in the 2nd quarter valued at $29,000. Finally, AWM Investment Company Inc. acquired a new position in shares of TriSalus Life Sciences during the 2nd quarter valued at $6,812,000. Hedge funds and other institutional investors own 2.58% of the company’s stock.

TriSalus Life Sciences Stock Performance

TriSalus Life Sciences stock opened at $6.43 on Thursday. TriSalus Life Sciences has a fifty-two week low of $3.42 and a fifty-two week high of $7.32. The company has a market capitalization of $321.24 million, a price-to-earnings ratio of -3.18 and a beta of 0.43. The stock has a fifty day moving average of $4.97 and a two-hundred day moving average of $4.94.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.79). The company had revenue of $11.57 million during the quarter, compared to analyst estimates of $11.76 million. On average, analysts forecast that TriSalus Life Sciences will post -1.55 EPS for the current fiscal year.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.